The monotherapy of ICIs (anti-programmed death 1 PD-1) has been shown to provide an overall survival benefit for selected NSCLC patients who have programmed death ligand 1 (PD-L1) expression on at least 50% of tumor cells (9, 10). The gene discussed is CD274; the disease is non-small cell lung carcinoma.